

Title (en)  
NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS

Title (de)  
NEUE VERWENDUNG VON PIPERAZIN-1-YLDIBENZO [B,F][1,4]THIAZEPIN ODER SEINES PHARMAZEUTISCH ANNEHMBAREN SALZES UND ORALE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN

Title (fr)  
NOUVELLE UTILISATION DE 11-PIPERAZINE-1-YLDIBENZO [B,F][1,4]THIAZEPINE OU DE SON SEL PHARMACEUTIQUEMENT ACCEPTABLE ET COMPOSITIONS PHARMACEUTIQUES ORALES

Publication  
**EP 1838325 A1 20071003 (EN)**

Application  
**EP 06700349 A 20060104**

Priority

- SE 2006000009 W 20060104
- US 64226205 P 20050107
- US 73788705 P 20051118
- US 73786505 P 20051118
- US 73786405 P 20051118

Abstract (en)  
[origin: WO2006073360A1] A method of treating at least one symptom or condition associated with but not limited to: 1) Substance-Related Disorders including but not limited to Substance Dependence, Substance Abuse, Substance Intoxication, Substance Withdrawal, Alcohol-Related Disorders, Amphetamine (or Amphetamine-Like)-Related Disorders, Caffeine-Related Disorders, Cannabis-Related Disorders, Cocaine-Related Disorders, Hallucinogen-Related Disorders, Inhalant-Related Disorders, Nicotine-Related Disorders, Opioid-Related Disorders, Phencyclidine (or Phencyclidine-Like)-Related Disorders, and Sedative-, Hypnotic- or Anxiolytic-Related Disorders. 2) Attention-Deficit and Disruptive Behavior Disorders. 3) Eating Disorders. 4) Personality Disorders including but not limited to Obsessive-Compulsive Personality Disorder. 5) Impulse-Control Disorders, comprising administering an effective amount of Formula I (I) or its pharmaceutically acceptable salt. In another aspect of the invention a pharmaceutical composition is provided comprising an effective amount of Formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier or diluent.

IPC 8 full level  
**A61K 31/554** (2006.01); **A61P 25/00** (2006.01); **A61P 25/20** (2006.01); **A61P 25/26** (2006.01); **A61P 25/30** (2006.01); **A61P 25/32** (2006.01); **A61P 25/36** (2006.01)

CPC (source: EP)  
**A61K 31/554** (2013.01); **A61P 3/00** (2017.12); **A61P 25/00** (2017.12); **A61P 25/20** (2017.12); **A61P 25/22** (2017.12); **A61P 25/26** (2017.12); **A61P 25/30** (2017.12); **A61P 25/32** (2017.12); **A61P 25/34** (2017.12); **A61P 25/36** (2017.12)

Citation (search report)  
See references of WO 2006073360A1

Citation (examination)  
COHRS S ET AL: "Sleep-promoting properties of quetiapine in healthy subjects", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 174, 1 January 2004 (2004-01-01), pages 421 - 429, XP002987369, ISSN: 0033-3158

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2006073360 A1 20060713**; AR 052191 A1 20070307; EP 1838325 A1 20071003; JP 2008526839 A 20080724; TW 200640466 A 20061201; UY 29326 A1 20060831

DOCDB simple family (application)  
**SE 2006000009 W 20060104**; AR P060100058 A 20060106; EP 06700349 A 20060104; JP 2007550327 A 20060104; TW 95100687 A 20060106; UY 29326 A 20060105